DCGI gives permission to BharatBiotech for intranasal booster dose trials

Prameyanews English

Published By : Prameya News Bureau | January 28, 2022 IST

New Delhi, Jan 28: The Drugs Controller General of India (DCGI) on Friday granted permission to BharatBiotech for intranasal booster dose trials. The BharatBiotech has proposed the booster dose for those who have been already been innoculated against Covid with Covishield and Covaxin vaccines. It aims to conduct clinical trials on 5,000 subjects – 50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin. The interval between the second dose and booster dose will be six months, sources said. The company had sought permission to conduct clinical trials for its intranasal booster dose in December last year.

News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp

You Might Also Like

More From Related News

Copyright © 2024 - Summa Real Media Private Limited. All Rights Reserved.